e-learning
resources
Milan 2017
Monday, 11.09.2017
Cystic fibrosis: treatments and monitoring
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Risk factors for lung disease progression in children with cystic fibrosis; a longitudinal cohort study
K. van de Kant (Maastricht, Netherlands)
Source:
International Congress 2017 – Cystic fibrosis: treatments and monitoring
Session:
Cystic fibrosis: treatments and monitoring
Session type:
Poster Discussion
Number:
1827
Disease area:
Airway diseases, Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. van de Kant (Maastricht, Netherlands). Risk factors for lung disease progression in children with cystic fibrosis; a longitudinal cohort study. 1827
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Evidence of early abnormal airways’ inflammation in children with type 1 diabetes
The impact of anti-IgE treatment on the airway microbiome in asthma.
Related content which might interest you:
Risk factors for lung disease progression in children with cystic fibrosis
Source: Eur Respir J, 51 (6) 1702509; 10.1183/13993003.02509-2017
Year: 2018
Risk factors for lung disease progression in children with cystic fibrosis
Source: Eur Respir J, 52 (4) 1801492; 10.1183/13993003.01492-2018
Year: 2018
Risk factors for progression of cystic fibrosis lung disease from childhood to adulthood
Source: Virtual Congress 2020 – Respiratory diseases in children and adults
Year: 2020
Prevalence and characteristics of cystic lung lesions in children with interstitial lung diseases – a register-based study
Source: Virtual Congress 2021 – Paediatric bronchology
Year: 2021
Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort
Source: Eur Respir J, 55 (4) 1901694; 10.1183/13993003.01694-2019
Year: 2020
Screening for cystic fibrosis among high risk group patients with chronic lung disease
Source: Eur Respir J 2002; 20: Suppl. 38, 340s
Year: 2002
Risk factors for postoperative acute exacerbation of interstitial lung diseases: a matched case-control study
Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives
Year: 2019
Factors affecting progression of lung disease among patients with cystic fibrosis
Source: International Congress 2019 – Physiology of cystic fibrosis
Year: 2019
Does the lung clearance index track with disease progression in early childhood?
Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Year: 2015
Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study
Source: Eur Respir J, 58 (3) 2002288; 10.1183/13993003.02288-2020
Year: 2021
Early deaths in cystic fibrosis: Analysis of causes and risk factors in a pediatric cohort
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems
Year: 2012
Early determinants of lung disease in children with cystic fibrosis
Source: Virtual Congress 2020 – New frontiers in cystic fibrosis imaging and lung physiology
Year: 2020
CF disease progress regarding lung symptoms – a cohort study
Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?
Year: 2007
Prospective evaluation of cardio-metabolic comorbidities in a cohort of patients with non-cystic fibrosis bronchiectasis.
Source: Virtual Congress 2020 – Interesting clinical problems for the respiratory physician
Year: 2020
Nutrition-related factors associated with waiting list mortality in patients with interstitial lung disease: a retrospective cohort study
Source: International Congress 2019 – Lung transplantation: from bench to bedside
Year: 2019
Occupational risk factors and idiopathic pulmonary fibrosis. A case-control study
Source: Annual Congress 2007 - The air we breathe at home and at work
Year: 2007
An observational study of incident diagnoses of children’s diffuse parenchymal lung disease (ChILDEU)
Source: International Congress 2018 – Primary ciliary dyskinesia and lung function tests in respiratory morbidities
Year: 2018
Longitudinal assessment of Lung Clearance Index as a marker of disease progression in a cohort of children with cystic fibrosis and normal spirometry
Source: Virtual Congress 2020 – New frontiers in cystic fibrosis imaging and lung physiology
Year: 2020
Impact of other risk factors than age at diagnosis on outcome in cystic fibrosis patients
Source: Eur Respir J 2006; 28: Suppl. 50, 715s
Year: 2006
Prospective cohort study of the alternate healthy eating index-2010 and risk of chronic obstructive pulmonary disease in US women and men
Source: Annual Congress 2013 –Environment and lifestyle: associations with respiratory disease
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept